Acorah Software Products - Accounts Production 19.1.200 false true 31 December 2024 1 July 2024 false 1 January 2025 30 June 2025 30 June 2025 04441512 Professor Mohammad Alavijeh A2E Capital Partners Limited Professor Mohammad Alavijeh Pharmidex Holdings Ltd true iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 04441512 2024-12-31 04441512 2025-06-30 04441512 2025-01-01 2025-06-30 04441512 frs-core:CurrentFinancialInstruments 2025-06-30 04441512 frs-core:Non-currentFinancialInstruments 2025-06-30 04441512 frs-core:BetweenOneFiveYears 2025-06-30 04441512 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-06-30 04441512 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-01-01 2025-06-30 04441512 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-12-31 04441512 frs-core:FurnitureFittings 2025-06-30 04441512 frs-core:FurnitureFittings 2025-01-01 2025-06-30 04441512 frs-core:FurnitureFittings 2024-12-31 04441512 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2025-06-30 04441512 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2025-01-01 2025-06-30 04441512 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2024-12-31 04441512 frs-core:MoreThanFiveYears 2025-06-30 04441512 frs-core:PlantMachinery 2025-06-30 04441512 frs-core:PlantMachinery 2025-01-01 2025-06-30 04441512 frs-core:PlantMachinery 2024-12-31 04441512 frs-core:WithinOneYear 2025-06-30 04441512 frs-core:RevaluationReserve 2025-01-01 2025-06-30 04441512 frs-core:RevaluationReserve 2024-12-31 04441512 frs-core:RevaluationReserve 2025-06-30 04441512 frs-core:SharePremium 2025-06-30 04441512 frs-core:ShareCapital 2025-06-30 04441512 frs-core:RetainedEarningsAccumulatedLosses 2025-06-30 04441512 frs-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-06-30 04441512 frs-bus:FilletedAccounts 2025-01-01 2025-06-30 04441512 frs-bus:SmallEntities 2025-01-01 2025-06-30 04441512 frs-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-06-30 04441512 frs-bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-06-30 04441512 frs-bus:OrdinaryShareClass1 2025-01-01 2025-06-30 04441512 frs-bus:OrdinaryShareClass1 2025-06-30 04441512 frs-bus:PreferenceShareClass1 2025-01-01 2025-06-30 04441512 frs-bus:PreferenceShareClass1 2025-06-30 04441512 1 2025-01-01 2025-06-30 04441512 frs-core:UnlistedNon-exchangeTraded 2025-06-30 04441512 frs-core:UnlistedNon-exchangeTraded 2024-12-31 04441512 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2024-12-31 04441512 frs-core:AdditionsToInvestments frs-core:UnlistedNon-exchangeTraded 2025-06-30 04441512 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2025-06-30 04441512 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 04441512 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2025-06-30 04441512 frs-bus:Director1 2025-01-01 2025-06-30 04441512 frs-bus:Director2 2025-01-01 2025-06-30 04441512 frs-bus:CompanySecretary1 2025-01-01 2025-06-30 04441512 frs-countries:EnglandWales 2025-01-01 2025-06-30 04441512 2024-06-30 04441512 2024-12-31 04441512 2024-07-01 2024-12-31 04441512 frs-core:CurrentFinancialInstruments 2024-12-31 04441512 frs-core:Non-currentFinancialInstruments 2024-12-31 04441512 frs-core:BetweenOneFiveYears 2024-12-31 04441512 frs-core:MoreThanFiveYears 2024-12-31 04441512 frs-core:PlantMachinery 2024-07-01 2024-12-31 04441512 frs-core:WithinOneYear 2024-12-31 04441512 frs-core:RevaluationReserve 2024-12-31 04441512 frs-core:SharePremium 2024-12-31 04441512 frs-core:ShareCapital 2024-12-31 04441512 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31 04441512 frs-bus:OrdinaryShareClass1 2024-07-01 2024-12-31 04441512 frs-bus:PreferenceShareClass1 2024-07-01 2024-12-31
Registered number: 04441512
Pharmidex Pharmaceutical Services Limited
Financial Statements
For the Period 1 January 2025 to 30 June 2025
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—8
Page 1
Balance Sheet
Registered number: 04441512
30 June 2025 31 December 2024
Notes £ £ £ £
FIXED ASSETS
Intangible Assets 4 446,110 479,388
Tangible Assets 5 2,157,240 1,717,312
Investments 6 19,243 -
2,622,593 2,196,700
CURRENT ASSETS
Stocks 7 670,115 702,726
Debtors 8 789,566 1,059,825
Cash at bank and in hand 435,708 208,755
1,895,389 1,971,306
Creditors: Amounts Falling Due Within One Year 9 (1,772,039 ) (1,640,550 )
NET CURRENT ASSETS (LIABILITIES) 123,350 330,756
TOTAL ASSETS LESS CURRENT LIABILITIES 2,745,943 2,527,456
Creditors: Amounts Falling Due After More Than One Year 10 (252,602 ) (301,730 )
PROVISIONS FOR LIABILITIES
Deferred Taxation (254,763 ) (157,482 )
NET ASSETS 2,238,578 2,068,244
CAPITAL AND RESERVES
Called up share capital 13 136,299 136,299
Share premium account 3,232,298 3,101,652
Revaluation reserve 15 772,589 604,425
Profit and Loss Account (1,902,608 ) (1,774,132 )
SHAREHOLDERS' FUNDS 2,238,578 2,068,244
Page 1
Page 2
For the period ending 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Professor Mohammad Alavijeh
Director
12 August 2025
The notes on pages 3 to 8 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Pharmidex Pharmaceutical Services Limited is a private company, limited by shares, incorporated in England & Wales, registered number 04441512 . The registered office is 167-169 Great Portland Street, Fifth Floor, London, W1W 5PF. The principal place of business is European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity; and
specific criteria have been met for each of the company's activities.
2.3. Research and Development
Service development costs are recognised as Intangible assets to the extent that future benefits are probable, that the developments are technically feasible, that there is a market for the services being developed, and that resources are available to complete the development. 
When the services become available for use, amortisation is provided on capitalised service development costs so as to write off the cost, less any estimated residual value, at 10% of cost per year.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets other than plant and machinery are measured at cost less accumulated depreciation and any accumulated impairment losses. 
Plant and machinery is measured at fair value less accumulated depreciation.
Depreciation is charged so as to write off the cost of assets over their estimated useful lives. Unless the useful life of a particular asset is determined to warrant a significantly different rate, when such rate will be used, depreciation is charged as follows:
Leasehold over the period of the lease
Plant & Machinery 10% of book value per year
Fixtures & Fittings 25% of book value per year
2.5. Leasing and Hire Purchase Contracts
Assets obtained under finance leases are capitalised as tangible fixed assets. Assets acquired under finance leases are depreciated over the shorter of the lease term and their useful lives. Assets acquired under hire purchase contracts are depreciated over their useful lives. Finance leases are those where substantially all of the benefits and risks of ownership are assumed by the company. Obligations under such agreements are included in the creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period.
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the profit and loss account as incurred.
2.6. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
2.7. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
Page 3
Page 4
2.8. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the profit and loss account because of items of income or expense that are taxable or deductible in other periods and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and asset reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
2.9. Pensions
The company operates a defined contribution pension scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.
2.10. Government Grant
Government grants are recognised in the profit and loss account in an appropriate manner that matches them with the expenditure towards which they are intended to contribute.
Grants for immediate financial support or to cover costs already incurred are recognised immediately in the profit and loss account. Grants towards general activities of the entity over a specific period are recognised in the profit and loss account over that period.
Grants towards fixed assets are recognised over the expected useful lives of the related assets.
2.11. Disclosure of short period
In order to optimise the company's financial position, these financial statements have been prepared to cover a six month period. The figures for the previous period also cover six months and are therefore entirely comparable.
3. Average Number of Employees
The average number of employees, including directors, during the period was 33 (2024: 35)
33 35
4. Intangible Assets
Development Costs
£
Cost
As at 1 January 2025 665,565
As at 30 June 2025 665,565
Amortisation
As at 1 January 2025 186,177
Provided during the period 33,278
As at 30 June 2025 219,455
...CONTINUED
Page 4
Page 5
Net Book Value
As at 30 June 2025 446,110
As at 1 January 2025 479,388
5. Tangible Assets
Land & Property
Leasehold Plant & Machinery Fixtures & Fittings Total
£ £ £ £
Cost or Valuation
As at 1 January 2025 47,992 2,443,046 198,592 2,689,630
Additions - 363,439 - 363,439
Revaluation - 174,341 - 174,341
As at 30 June 2025 47,992 2,980,826 198,592 3,227,410
Depreciation
As at 1 January 2025 11,998 794,992 165,328 972,318
Provided during the period 2,399 91,295 4,158 97,852
As at 30 June 2025 14,397 886,287 169,486 1,070,170
Net Book Value
As at 30 June 2025 33,595 2,094,539 29,106 2,157,240
As at 1 January 2025 35,994 1,648,054 33,264 1,717,312
Plant and machinery was revalued by the directors during the year by reference to sales values available in the market place for plant and machinery of similar age and condition.
Included above are assets held under finance leases or hire purchase contracts with a net book value as follows:
30 June 2025 31 December 2024
£ £
Plant & Machinery 481,936 730,574
If the following tangible fixed assets had been accounted for under historical cost accounting rules, the amounts would be:
Plant & Machinery
£
Cost 2,581,921
Accumulated depreciation and impairment 1,370,630
Carrying amount 1,211,291
Page 5
Page 6
6. Investments
Unlisted
£
Cost or Valuation
As at 1 January 2025 -
Additions 19,243
As at 30 June 2025 19,243
Provision
As at 1 January 2025 -
As at 30 June 2025 -
Net Book Value
As at 30 June 2025 19,243
As at 1 January 2025 -
7. Stocks
30 June 2025 31 December 2024
£ £
Materials 147,698 123,069
Work in progress 522,417 579,657
670,115 702,726
8. Debtors
30 June 2025 31 December 2024
£ £
Due within one year
Trade debtors 331,972 385,738
Prepayments and accrued income 105,279 210,696
Other debtors 89,473 126,328
Corporation tax recoverable assets 114,717 337,063
Amounts owed by group undertakings 148,125 -
789,566 1,059,825
Page 6
Page 7
9. Creditors: Amounts Falling Due Within One Year
30 June 2025 31 December 2024
£ £
Net obligations under finance lease and hire purchase contracts 197,751 221,109
Trade creditors 1,398,847 1,132,335
Bank loans and overdrafts 10,015 10,016
Other taxes and social security 111,993 231,698
Other creditors 23,656 16,276
Accruals and deferred income 10,827 4,316
Amounts owed to related parties 18,950 24,800
1,772,039 1,640,550
10. Creditors: Amounts Falling Due After More Than One Year
30 June 2025 31 December 2024
£ £
Net obligations under finance lease and hire purchase contracts 248,435 286,167
Bank loans 4,167 9,167
Amounts owed to related parties - 6,396
252,602 301,730
11. Secured Creditors
Of the creditors the following amounts are secured on the assets to which they relate.
30 June 2025 31 December 2024
£ £
Net obligations under finance lease and hire purchase contracts 446,186 507,276
Other Creditors 18,949 31,195
12. Obligations Under Finance Leases and Hire Purchase
30 June 2025 31 December 2024
£ £
The future minimum finance lease payments are as follows:
Not later than one year 197,751 221,109
Later than one year and not later than five years 248,435 286,167
446,186 507,276
446,186 507,276
Page 7
Page 8
13. Share Capital
30 June 2025 31 December 2024
Allotted, called up and fully paid £ £
19,611 Ordinary Shares of £ 1 each 19,611 19,611
Preference Shares
30 June 2025 31 December 2024
Allotted, called up and fully paid £ £
116,688 Preference Shares of £ 1 each 116,688 116,688
14. Other Commitments
Amounts not provided for in the balance sheet
The total of future minimum lease payments under non-cancellable operating leases not provided for in the balance sheet, which are in respect of ongoing office and laboratory facilities, are as follows:
30 June 2025 31 December 2024
£ £
Not later than one year 480,767 480,766
Later than one year and not later than five years 1,918,512 1,918,512
Later than five years 939,812 700,795
3,339,091 3,100,073
15. Reserves
Revaluation Reserve
£
As at 1 January 2025 604,425
Surplus on revaluation 168,164
As at 30 June 2025 772,589
16. Ultimate Controlling Party
The company's ultimate controlling party is Pharmidex Holdings Ltd by virtue of its ownership of 100% of the issued share capital in the company.
Page 8